In this regard, inhibitors of YAP, as well as TAZ, may provide a novel and effective option by exploiting multiple hits to cancer cells; optimising tumour regression, diminishing the resistance and enhancing sensitisation to various chemotherapy agents, reducing the time to relapse, and as neoadjuvant or adjuvant therapy to enhance responsiveness to systemic agents and radiotherapy/surgery [123,132,135]. This evidence concerns the gene YAP1 and neoplasm.